The stock has surged 38% in six months on strong drug and MedTech growth, closing recently at $248.43. Recent returns are strong, with a 19.8% gain year-to-date and 54.7% over one year. However, the company faces potential headwinds from upcoming patent losses and ongoing lawsuits. A key pipeline drug, zanidatamab, has a regulatory application target for early 2026 in the U.S., with potential launch in late 2026, which could bring significant milestone payments.